Reportlinker Adds Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, April 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Uveitis Therapeutics market. The report identifies the key trends shaping and driving the global Uveitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Uveitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Uveitis Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Uveitis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Uveitis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Uveitis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Uveitis Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Uveitis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Uveitis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Uveitis Therapeutics market landscape? – Identify, understand and capitalize.
Table of Contents
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Uveitis Therapeutics: Introduction 6
2.1 Overview 6
2.2 Etiology and Pathophysiology 7
2.3 Epidemiology 8
2.4 Symptoms 8
2.5 Diagnosis 8
2.5.1 Visual Acuity and External Examination: 8
2.5.2 Slit-lamp Examination: 8
2.5.3 Tonometry 8
2.5.4 Supplemental Examination: 9
2.6 Treatment and Management Pattern 9
2.7 GlobalData Pipeline Report Guidance 10
3 Uveitis Therapeutics: Market Characterization 11
3.1 Overview 11
3.2 Uveitis Therapeutics Market Size 11
3.3 Uveitis Therapeutics Market Size (2005-2010) – Global 11
3.4 Uveitis Therapeutics Market Forecast (2010-2017) – Global 12
3.5 Uveitis Therapeutics Market Size (2005-2010) –US 13
3.6 Uveitis Therapeutics Market Forecast (2010-2017) – US 14
3.7 Uveitis Therapeutics Market Size (2005-2010) – France 15
3.8 Uveitis Therapeutics Market Forecast (2010-2017) – France 16
3.9 Uveitis Therapeutics Market Size (2005-2010) – Germany 17
3.10 Uveitis Therapeutics Market Forecast (2010-2017) – Germany 18
3.11 Uveitis Therapeutics Market Size (2005-2010) – Italy 19
3.12 Uveitis Therapeutics Market Forecast (2010-2017) – Italy 20
3.13 Uveitis Therapeutics Market Size (2005-2010) – Spain 21
3.14 Uveitis Therapeutics Market Forecast (2010-2017) – Spain 22
3.15 Uveitis Therapeutics Market Size (2005-2010) – UK 23
3.16 Uveitis Therapeutics Market Forecast (2010-2017) – UK 24
3.17 Uveitis Therapeutics Market Size (2005-2010) – Japan 25
3.18 Uveitis Therapeutics Market Forecast (2010-2017) – Japan 26
3.19 Drivers and Barriers 27
3.19.1 Drivers for the Uveitis Therapeutics Market 27
3.19.2 Barriers for the Uveitis Therapeutics Market 27
3.20 Opportunity and Unmet needs 28
3.21 Key Takeaway 29
4 Uveitis Therapeutics Market – Competitive Assessment 30
4.1 Overview 30
4.2 Strategic Competitor Assessment 30
4.3 Product Profile for the Major Marketed Products in Uveitis Therapeutics Market 31
4.3.1 Overview 31
4.3.2 Corticosteroids 31
4.3.3 Immunosuppressants 31
4.4 Key Takeaway 31
5 Uveitis Therapeutics: Pipeline Assessment 32
5.1 Overview 32
5.2 Strategic Pipeline Assessment 32
5.3 Pipeline by Phases of Development 32
5.3.1 Uveitis Therapeutics – Regulatory Filed Products 32
5.3.2 Uveitis Therapeutics-Phase III Pipeline 33
5.3.3 Uveitis Therapeutics-Phase II Pipeline 33
5.3.4 Uveitis Therapeutics-Phase I Pipeline 33
5.3.5 Uveitis Therapeutics-Pre-Clinical Pipeline 33
5.4 Uveitis Therapeutics Market– Clinical Pipeline by Mechanism of Action. 34
5.5 Technology Trends Analytic Framework 35
5.6 Promising Drugs Under Clinical Development 36
5.7 Profile for Promising Drugs 37
5.7.1 Luveniq 37
5.7.2 AIN457 38
5.7.3 Humira 39
5.8 Key Takeaway 39
6 Uveitis Therapeutics:Clinical Trials Mapping 40
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 40
6.2 Clinical Trials by Phase 41
6.3 Clinical Trials by Trial Status 42
6.4 Prominent Sponsors 43
6.5 Top Ten Companies Participating in Therapeutics Clinical Trials 44
7 Uveitis Therapeutics:Strategic Assessment 45
7.1 Key Events Impacting the Future Market 45
7.2 Future Market Competition Scenario 45
8 Uveitis:Future Players 47
8.1 Introduction 47
8.2 Company Profiles 47
8.2.1 Lux Biosciences 47
8.2.2 Novartis 48
8.2.3 Abbott Laboratories 51
8.2.4 Allergan 53
8.3 Other Companies in Uveitis Therapeutics Market 56
9 Uveitis Therapeutics: Liscensing and Partnership Deals 57
10 Appendix 58
10.1 Market Definitions 58
10.2 Abbreviations 58
10.3 Research Methodology 58
10.3.1 Coverage 59
10.3.2 Secondary Research 59
10.3.3 Forecasting 59
10.3.4 Primary Research 62
10.3.5 Expert Panel Validation 62
10.4 Contact Us 62
10.5 Disclaimer 62
10.6 Bibliography 63
List of Tables
1.1 List of Tables
Table 1: Uveitis- Anatomical Classification 6
Table 2: Uveitis- Classification Based On Severity 6
Table 3: Uveitis Therapeutics Market, Global, Revenue ($m), 2005-2010 12
Table 4: Uveitis Therapeutics Market, Global, Forecast ($m), 2010-2017 12
Table 5: Uveitis Therapeutics Market, US, Revenue ($m), 2005-2010 13
Table 6: Uveitis Therapeutics Market, US, Forecast ($m), 2010-2017 14
Table 7: Uveitis Therapeutics Market, France, Revenue ($m), 2005-2010 15
Table 8: Uveitis Therapeutics Market, France, Forecast ($m), 2010-2017 16
Table 9: Uveitis Therapeutics Market, Germany, Revenue ($m), 2005-2010 17
Table 10: Uveitis Therapeutics Market, Germany, Forecast ($m), 2010-2017 18
Table 11: Uveitis Therapeutics Market, Italy, Revenue ($m), 2005-2010 19
Table 12: Uveitis Therapeutics Market, Italy, Forecast ($m), 2010-2017 20
Table 13: Uveitis Therapeutics Market, Spain, Revenue ($m), 2005-2010 21
Table 14: Uveitis Therapeutics Market, Spain, Forecast ($m), 2010-2017 22
Table 15: Uveitis Therapeutics Market, UK, Revenue ($m), 2005-2010 23
Table 16: Uveitis Therapeutics Market, UK, Forecast ($m), 2010-2017 24
Table 17: Uveitis Therapeutics Market, Japan, Revenue ($m), 2005-2010 25
Table 18: Uveitis Therapeutics Market, Japan, Forecast ($m), 2010-2017 26
Table 19: Uveitis Therapeutics – Regulatory Filed Products, 2011 32
Table 20: Uveitis Therapeutics – Phase III Pipeline, 2011 33
Table 21: Uveitis Therapeutics – Phase II Pipeline, 2011 33
Table 22: Uveitis Therapeutics – Phase I Pipeline, 2011 33
Table 23: Uveitis Therapeutics – Pre-Clinical Pipeline, 2011 33
Table 24: Uveitis Therapeutics – Most Promising Drugs Under Clinical Development, 2011 36
Table 25: Uveitis Therapeutics Market-Clinical Trials by Region, 2010 40
Table 26: Uveitis Therapeutics Market, Global, Clinical Trials by Phase of Development, 2010 41
Table 27: Uveitis Therapeutics Market, Global, Clinical Trials by Trial Status, 2010 42
Table 28: Uveitis Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2010 44
Table 29: Uveitis Therapeutics Market, Global, Clinical Trials by Top Companies, 2010 44
Table 30: Lux Biosciences – Ophthalmology Pipeline Products, 2010 48
Table 31: Lux Biosciences – Ophthalmology Pipeline Products, 2010 48
Table 32: Novartis – Ophthalmology Pipeline Products, 2010 49
Table 33: Novartis – Ophthalmology Pipeline Products, 2010 49
Table 34: Novartis-Deals, 2009-2011 50
Table 35: Novartis – Ophthalmology Pipeline Products, 2010 52
Table 36: Abbott Laboratories- Deals, 2009-2011 52
Table 37: Novartis – Ophthalmology Pipeline Products, 2010 55
Table 38: Allergan-Deals, 2010-2011 55
Table 39: Uveitis Therapeutics Market – Future Players, 2010 56
Table 40: Uveitis Therapeutics, Global, Deals, 2009-2011 57
List of Figures
1.2 List of Figures
Figure 1: Etiology of Uveitis 7
Figure 2: Uveitis - Treatment and Management Pattern 9
Figure 3: Uveitis Therapeutics Market, Global, Revenue ($m), 2005-2010 11
Figure 4: Uveitis Therapeutics Market, Global, Forecast ($m), 2010-2017 12
Figure 5: Uveitis Therapeutics Market, US, Revenue ($m), 2005-2010 13
Figure 6: Uveitis Therapeutics Market, US, Forecast ($m), 2010-2017 14
Figure 7: Uveitis Therapeutics Market, France, Revenue ($m), 2005-2010 15
Figure 8: Uveitis Therapeutics Market, France, Forecast ($m), 2010-2017 16
Figure 9: Uveitis Therapeutics Market, Germany, Revenue ($m), 2005-2010 17
Figure 10: Uveitis Therapeutics Market, Germany, Forecast ($m), 2010-2017 18
Figure 11: Uveitis Therapeutics Market, Italy, Revenue ($m), 2005-2010 19
Figure 12: Uveitis Therapeutics Market, Italy, Forecast ($m), 2010-2017 20
Figure 13: Uveitis Therapeutics Market, Spain, Revenue ($m), 2005-2010 21
Figure 14: Uveitis Therapeutics Market, Spain, Forecast ($m), 2010-2017 22
Figure 15: Uveitis Therapeutics Market, UK, Revenue ($m), 2005-2010 23
Figure 16: Uveitis Therapeutics Market, UK, Forecast ($m), 2010-2017 24
Figure 17: Uveitis Therapeutics Market, Japan, Revenue ($m), 2005-2010 25
Figure 18: Uveitis Therapeutics Market, Japan, Forecast ($m), 2010-2017 26
Figure 19: Opportunity and Unmet Need in the Uveitis Therapeutics Market, 2010 28
Figure 20: Strategic Competitor Assessment of the Major Marketed Products in Uveitis, 2010 30
Figure 21: Uveitis Therapeutics Pipeline by Phase of Clinical Development, 2011 32
Figure 22: Uveitis Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2011 34
Figure 23: Technology Trends Analytic Framework of the Uveitis Therapeutics Pipeline, 2011 35
Figure 24: Technology Trends Analytic Framework of the Uveitis Therapeutics Pipeline- Description, 2011 36
Figure 25: Luveniq- Clinical Trial Details 37
Figure 26: AIN457- Clinical Trial Details 38
Figure 27: Humira- Clinical Trial Details 39
Figure 28: Uveitis Therapeutics Market-Clinical Trials by Region, 2010 40
Figure 29: Uveitis Therapeutics Market, Global, Clinical Trials by Phase of Development, 2010 41
Figure 30: Uveitis Therapeutics Market, Global, Clinical Trials by Trial Status, 2010 42
Figure 31: Uveitis Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2010 43
Figure 32: Uveitis Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2010 43
Figure 33: Uveitis Therapeutics Market, Global, Clinical Trials by Top Companies, 2010 44
Figure 34: Key Events Competition in the Uveitis, 2010 45
Figure 35: Implications for Future Market Competition in the Uveitis, 2010 46
Figure 36: Uveitis Therapeutics Market – Clinical Pipeline by Company, 2010 47
Figure 37: GlobalData Market Forecasting Model 61
To order this report:
: Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article